Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

ICON launches FIRECREST Financial Disclosure to Reduce Administrative Costs and Increase Regulatory Compliance


, (NASDAQ:ICLR) a global provider of drug development and
commercialisation solutions and services, today announced the launch of
FIRECREST Financial Disclosure, an innovative digital solution that
increases the efficiency and compliance of investigator Financial
Disclosure administration. FIRECREST Financial Disclosure provides a
robust solution for sponsors to distribute, track and manage the
completion of forms mandated by FDA 21CFR Part 54 (Financial Disclosure
by Clinical Investigators). The solution enables secure, centralised,
electronic distribution and response capture of Financial Disclosure

ICON has developed FIRECREST Financial Disclosure to address the ongoing
industry challenge of non-compliance due to incomplete forms and to
ensure necessary regulatory requirements are in place in advance of
study start-up. The solution reduces the risk of regulatory findings and
reduces administrative costs associated with traditional distribution
and tracking of form completion.

"FIRECREST Financial Disclosure supports sponsors to increase compliance
and manage the Financial Disclosure process more efficiently." commented
Mark Connolly, VP FIRECREST at ICON. "We estimate the solution is
capable of delivering savings in excess of 50% when compared to
traditional methods, while also contributing to the environmental
sustainability targets of our clients".

Financial Disclosure is the latest addition to the FIRECREST digital
solutions suite, developed to increase efficiency in clinical trials by
driving site performance. Solutions include award winning GCP and
Protocol Training Animations, Visit By Visit Guide, Trial Drive and
Pre-Screen. To learn more about FIRECREST, visit

About ICON plc

ICON plc is a global provider of outsourced drug development and
commercialisation solutions and services to pharmaceutical,
biotechnology, medical device, and government and public health
organisations. The company specializes in the strategic development,
management and analysis of programs that support clinical development
from compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently, operates from 97
locations in 38 countries and has approximately 13,380 employees.

Further information is available at

This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at


View Comments and Join the Discussion!